A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma

Sponsor
The First Affiliated Hospital of Zhengzhou University
Study ID
NCT03521219
Phase
PHASE2
Status
Unknown

Conditions

  • Intrahepatic Cholangiocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.

Study Details

The propose of this study is to confirm safety and efficacy of Apatinib monotherapy in patients with advanced cholangiocarcinoma.

Key Dates

Start date
Feb 7, 2018
Status verified
May 2018
Primary completion
Nov 30, 2018
Completion
Nov 30, 2019

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib
    Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.

Primary Outcome Measure

Disease Control Rate (DCR) [ Time Frame: 1 month ]

Central Contacts

Related Studies